Testosterone replacement therapy (TRT) can be life-changing for men with properly diagnosed hypogonadism. It can also cause side effects and requires careful monitoring. My own experience with TRT was complicated, and the most important lesson I took from it is this: personal experience matters, but it should not be mistaken for proof that TRT is broadly unsafe.
Who Should Be Diagnosed With Hypogonadism?
The Endocrine Society recommends diagnosing hypogonadism only when a man has compatible symptoms and consistently low testosterone levels measured accurately, usually confirmed with repeat morning testing.
Symptoms such as low energy, reduced libido, mood changes, or poor exercise recovery are not specific to testosterone deficiency. Sleep problems, obesity, medications, depression, chronic illness, and other conditions can produce similar symptoms.
What TRT Can Help
In appropriately selected men with true hypogonadism, testosterone therapy can improve sexual function, maintain secondary sex characteristics, increase lean mass, and help correct some consequences of androgen deficiency.
What Are the Main Risks and Side Effects?
- Erythrocytosis: testosterone can increase hematocrit and requires monitoring.
- Reduced fertility: exogenous testosterone can suppress sperm production.
- Acne and oily skin
- Fluid retention
- Prostate-related monitoring needs
- Possible cardiovascular and thromboembolic signals: risk depends on the patient and remains an area of ongoing study.
What the TRAVERSE Trial Changed
The large TRAVERSE randomized trial included more than 5,000 men with confirmed hypogonadism and cardiovascular disease or high cardiovascular risk. Testosterone therapy was not associated with a higher rate of major cardiovascular events such as cardiovascular death, heart attack, or stroke compared with placebo.
However, higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism were observed in the testosterone group. A later fracture analysis also found more clinical fractures among men assigned to testosterone.
That is a good example of why “TRT is safe” and “TRT is dangerous” are both oversimplifications.
My Experience With TRT
I had a difficult experience with testosterone that included appetite changes, acne, fluid retention, mood changes, and episodes of dizziness. Reducing and eventually stopping TRT coincided with improvement in several of those symptoms.
That experience was meaningful for me, but it does not prove that testosterone caused every symptom or that mechanisms such as “detoxification failure,” heavy metals, parasites, or genetic SNPs explained the reaction. Looking back, those interpretations were much more speculative than I would present them today.
Who Should Avoid or Delay TRT?
Current Endocrine Society guidance recommends against starting testosterone in several situations, including men planning fertility in the near term, men with certain prostate or breast cancers, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, recent myocardial infarction or stroke, or thrombophilia.
Individual risks should be reviewed with the prescribing clinician.
What Monitoring Matters?
- Symptoms and treatment response
- Serum testosterone
- Hematocrit/hemoglobin
- Prostate risk and PSA when appropriate
- Blood pressure and cardiovascular risk
- Fertility goals
- Adverse effects such as edema, acne, mood changes, or sleep apnea symptoms
What About “Functional” Low Testosterone?
The Endocrine Society emphasized again in 2026 that obesity, medications, and other reversible factors should be addressed before assuming testosterone replacement is the best solution. In some men with obesity-associated low testosterone, weight loss and treatment of the underlying metabolic issue may improve testosterone levels.
The Bottom Line
TRT is neither a miracle drug nor inherently dangerous. It is a medical treatment that can be appropriate for men with confirmed hypogonadism when benefits and risks are weighed carefully and monitoring is done correctly.
My own negative experience is one reason I care deeply about individualized care—but evidence should guide the broader conclusion.
References
- Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources. Endocrine Society.
- Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026. Endocrine Society.
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023. PubMed.
- Snyder PJ, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024. PubMed.
